Axitinib and Sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Cell Communication and Signaling. 14 (2016), 6, DOI 10.1186/s12964-016-0129-y, issn: 1478-811X
IN COPYRIGHT http://rightsstatements.org/page/InC/1.0 rs
- Schlagwort
-
Chronisch-myeloische Leukämie
Imatinib mesilat
Biopharmazie
Pharmakodynamik
Pharmakokinetik
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2016
- Beteiligte Personen und Organisationen
-
Zentrum für Biosystemanalyse
Albert-Ludwigs-Universität Freiburg. Freiburg Institute of Advanced Studies
Universitäts-Hautklinik. Freiburg im Breisgau
Albert-Ludwigs-Universität Freiburg. Institut für Molekulare Medizin und Zellforschung
Albert-Ludwigs-Universität Freiburg. Medizinische Fakultät
Albert-Ludwigs-Universität Freiburg. Fakultät für Biologie
Spemann Graduate School of Biology and Medicine
Albert-Ludwigs-Universität Freiburg
- DOI
-
10.1186/s12964-016-0129-y
- URN
-
urn:nbn:de:bsz:25-freidok-125999
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:50 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Halbach, Sebastian
- Hu, Zehan
- Gretzmeier, Christine
- Ellermann, Julia
- Dengjel, Jörn
- Zentrum für Biosystemanalyse
- Albert-Ludwigs-Universität Freiburg. Freiburg Institute of Advanced Studies
- Universitäts-Hautklinik. Freiburg im Breisgau
- Albert-Ludwigs-Universität Freiburg. Institut für Molekulare Medizin und Zellforschung
- Albert-Ludwigs-Universität Freiburg. Medizinische Fakultät
- Albert-Ludwigs-Universität Freiburg. Fakultät für Biologie
- Spemann Graduate School of Biology and Medicine
- Albert-Ludwigs-Universität Freiburg
- Universität
Entstanden
- 2016
Ähnliche Objekte (12)
Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia
Sorafenib : Sorafenib in der Behandlung des Radiojod-refraktären differenzierten Schilddrüsenkarzinoms
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Comparative response of nine hepatoma cell lines to the four tyrosine kinase inhibitors, sorafenib, lenvatinib, regorafenib and cabozantinib
Analysis of the impact of Bruton Tyrosine Kinase on Myeloid Cell Development and Function
Optimierung der Sorafenib-Therapie
Discovery and mechanistic analysis of a sorafenib-derived antibiotic active against drug-resistant S. aureus, persisters and biofilms
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Investigation of resistance mechanisms in acute myeloid leukaemia towards tyrosine kinase inhibitors with mass spectrometry
Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Oxidation of protein tyrosine phosphatases as an oncogenic event in FLT3-ITD positive acute myeloid leukemia
NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors
Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia
Sorafenib : Sorafenib in der Behandlung des Radiojod-refraktären differenzierten Schilddrüsenkarzinoms
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Comparative response of nine hepatoma cell lines to the four tyrosine kinase inhibitors, sorafenib, lenvatinib, regorafenib and cabozantinib
Analysis of the impact of Bruton Tyrosine Kinase on Myeloid Cell Development and Function
Optimierung der Sorafenib-Therapie
Discovery and mechanistic analysis of a sorafenib-derived antibiotic active against drug-resistant S. aureus, persisters and biofilms
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Investigation of resistance mechanisms in acute myeloid leukaemia towards tyrosine kinase inhibitors with mass spectrometry
Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Oxidation of protein tyrosine phosphatases as an oncogenic event in FLT3-ITD positive acute myeloid leukemia
NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors
Gab2 and its role in Tyrosine Kinase Inhibitor Resistance in chronic myeloid leukemia
Sorafenib : Sorafenib in der Behandlung des Radiojod-refraktären differenzierten Schilddrüsenkarzinoms
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Comparative response of nine hepatoma cell lines to the four tyrosine kinase inhibitors, sorafenib, lenvatinib, regorafenib and cabozantinib
Analysis of the impact of Bruton Tyrosine Kinase on Myeloid Cell Development and Function
Optimierung der Sorafenib-Therapie
Discovery and mechanistic analysis of a sorafenib-derived antibiotic active against drug-resistant S. aureus, persisters and biofilms
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Investigation of resistance mechanisms in acute myeloid leukaemia towards tyrosine kinase inhibitors with mass spectrometry
Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Oxidation of protein tyrosine phosphatases as an oncogenic event in FLT3-ITD positive acute myeloid leukemia